Zidesamtinib targets ROS1-positive NSCLC, showing promise in overcoming resistance mutations and CNS metastases with brain penetrance. The ARROS-1 trial demonstrated significant response rates in TKI ...

(RTTNews) - Nuvalent Inc. (NUVL) announced that its New Drug Application seeking approval of Zidesamtinib for treating adult patients with advanced ROS1-positive non-small cell lung cancer has been ...

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE backed the drug in England. Rozlytrek (entrectinib) ...

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), ...

Nuvalent Inc. (NASDAQ:NUVL) is one of the best 52-week high stocks to buy right now. On November 24, Truist Securities ...

Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM ESTCompany ParticipantsDavid Hung - Founder, President, ...

Can you get lung cancer without smoking? Yes. A leading oncologist explains the key differences in diagnosis, treatment, and ...

Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Nuvation Bio stock is downgraded as price reflects Ibtrozi’s strong launch. Get insights on NUVB stock's forward revenue and investor strategies.

Solihull mum-of-one Catherine Paul felt her body had 'betrayed' her after a cancer diagnosis - despite an organic diet and regular exercise ...

Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...